ES2525410T3 - Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas - Google Patents

Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas Download PDF

Info

Publication number
ES2525410T3
ES2525410T3 ES06728342.4T ES06728342T ES2525410T3 ES 2525410 T3 ES2525410 T3 ES 2525410T3 ES 06728342 T ES06728342 T ES 06728342T ES 2525410 T3 ES2525410 T3 ES 2525410T3
Authority
ES
Spain
Prior art keywords
compositions
treatment
methods
hyperproliferative diseases
dermal hyperproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06728342.4T
Other languages
English (en)
Inventor
Avikam Harel
Zeev Even-Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermipsor Ltd
Original Assignee
Dermipsor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermipsor Ltd filed Critical Dermipsor Ltd
Application granted granted Critical
Publication of ES2525410T3 publication Critical patent/ES2525410T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica de aplicación tópica que consta esencialmente de calcipotriol, nicotinamida, y un portador dermatológicamente aceptable basado en polietilenglicol, en la que el portador comprende PEG - 4000, PEG - 400 y alcohol estearílico polioxietilado (Steareth - 20).

Description

Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
ES06728342.4T 2005-05-10 2006-05-10 Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas Active ES2525410T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67955605P 2005-05-10 2005-05-10
US679556P 2005-05-10
PCT/IL2006/000553 WO2006120682A2 (en) 2005-05-10 2006-05-10 Compositions and methods for treating hyperproliferative epidermal diseases

Publications (1)

Publication Number Publication Date
ES2525410T3 true ES2525410T3 (es) 2014-12-22

Family

ID=37396970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06728342.4T Active ES2525410T3 (es) 2005-05-10 2006-05-10 Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas

Country Status (15)

Country Link
US (3) US9173835B2 (es)
EP (1) EP1879595B1 (es)
JP (1) JP2008540514A (es)
KR (1) KR20080012339A (es)
CN (1) CN101193641B (es)
AU (1) AU2006245283B2 (es)
BR (1) BRPI0609630A2 (es)
CA (1) CA2608023C (es)
DK (1) DK1879595T3 (es)
ES (1) ES2525410T3 (es)
HK (1) HK1112194A1 (es)
IL (1) IL187238A (es)
NZ (1) NZ563270A (es)
WO (1) WO2006120682A2 (es)
ZA (1) ZA200710371B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
CN101193641B (zh) * 2005-05-10 2013-05-29 德米普瑟尔有限公司 用于治疗表皮过度增殖疾病的组合物和方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CA2814135A1 (en) * 2010-10-10 2012-04-19 Dermipsor Ltd. Compositions for treating psoriasis of the scalp
IT1406273B1 (it) * 2010-12-15 2014-02-14 Lismi Srl Composizione per il trattamento topico della psoriasi e degli inestetismi cutanei collegati
CA2834395A1 (en) * 2011-04-27 2012-11-01 Northshore University Healthsystem Compositions and methods
CN102988987B (zh) * 2012-12-13 2014-06-18 西安力邦制药有限公司 一种用于治疗表皮过度增殖疾病的药物组合物及其制剂
EP3191103B1 (en) * 2014-09-10 2021-09-01 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
FR3045385B1 (fr) * 2015-12-22 2019-12-20 Jean-Noel Thorel Composition cosmetique comprenant des inhibiteurs de l'expression du facteur de croissance nerveuse (nerve growth factor) pour le traitement du psoriasis, de la dermatite atopique et du prurit
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
KR102560269B1 (ko) * 2017-03-24 2023-07-28 조이더마 아게 약제학적 조성물
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
GB2597526A (en) * 2020-07-27 2022-02-02 Incanthera R&D Ltd Topical formulation
WO2022023348A1 (en) * 2020-07-27 2022-02-03 Incanthera (R&D) Ltd Topical formulation

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1510108A (en) * 1974-05-28 1978-05-10 Nat Res Dev Spectrometers
US4067975A (en) 1975-08-04 1978-01-10 Yu Ruey J Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide
US4505896A (en) 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3106748A1 (de) * 1981-02-24 1982-09-09 Dynamit Nobel Ag, 5210 Troisdorf Impraegnierungsmittel fuer cellulosehaltiges material
US4434183A (en) * 1982-09-27 1984-02-28 Pennwalt Corporation Use of haloprogin to treat Herpes labialis
US4594432A (en) * 1983-01-28 1986-06-10 Hoffman-La Roche Inc. Process for the synthesis of 1α,23(S),25-trihydroxycholecalciferol and 1α,23(R),25-trihydroxycholecalciferol
USRE33107E (en) * 1983-03-22 1989-11-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US4719205A (en) * 1984-01-30 1988-01-12 Wisconsin Alumini Research Foundation Side-chain unsaturated 1-hydroxyvitamin D compounds
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
CA1272953A (en) 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
US5037816A (en) 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
JPH07100685B2 (ja) 1985-08-02 1995-11-01 レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ／エス（レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ） 新規ビタミンｄ類似体
US4855142A (en) * 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
US4804502A (en) 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
US5831074A (en) 1988-11-02 1998-11-03 Strumwasser; Felix Eucaryotic NAD cyclases
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB9007236D0 (en) 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
US5194248A (en) 1990-06-21 1993-03-16 Trustees Of Boston University Compositions comprising vitamin D analog precursors and the use thereof
GB9017890D0 (en) 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE69213844T2 (de) 1991-07-05 1997-04-10 Duphar Int Res Vitamin-D Derivat, Verfahren zu dessen Herstellung sowie Zwischenprodukte dafür
US5254331A (en) * 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
HU209067B (en) 1991-12-30 1994-03-28 Tatar Process for the production of hair-fall moderating preparation
TW233264B (es) * 1992-02-03 1994-11-01 Otsuka Pharma Co Ltd
GB9206648D0 (en) 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
DE4335454A1 (de) 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5430049A (en) 1993-12-08 1995-07-04 Gaut; Zane N. Treating hyperproliferative disorders
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
US5519059A (en) * 1994-08-17 1996-05-21 Sawaya; Assad S. Antifungal formulation
JPH0873338A (ja) 1994-09-02 1996-03-19 Noevir Co Ltd 皮膚外用剤
JPH11514999A (ja) 1995-10-10 1999-12-21 ストルーブ，マリリン ビタミンｄおよびその誘導体による掻痒症治療
US5747479A (en) 1996-01-03 1998-05-05 Hoffmann-La Roche Inc. Vitamin D3 analogs useful for reversing the photodamage in sun-exposed skin
GB9600545D0 (en) * 1996-01-11 1996-03-13 Ciba Geigy Ag Compositions
DK0892638T3 (da) 1996-04-04 2003-03-03 Cilag Ag Liposombaseret, topisk vitamin D-præparat
EP0900185B1 (en) 1996-05-02 2001-03-14 Duphar International Research B.V Vitamin d analogs and methods of preparing these compounds
JPH10139669A (ja) 1996-11-05 1998-05-26 Teijin Ltd 脂漏性角化症治療剤
US5811414A (en) 1997-05-16 1998-09-22 Hoffmann-La Roche Inc. Vitamin D3 analogs useful for reversing the photodamage in sun-exposed skin
US6429218B1 (en) 1997-05-19 2002-08-06 Joseph Scivoletto Method of controlling niacin concentration in lotion
US6248763B1 (en) 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
USH2013H1 (en) 1997-05-23 2002-02-05 The Procter & Gamble Company Skin care compositions
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6262041B1 (en) 1998-04-06 2001-07-17 Bertek Pharmaceuticals, Inc. Use of vitamin D analogs to treat conditions related to increased oxidative stress
US6107349A (en) 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US20010002396A1 (en) 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US6753013B1 (en) * 1999-04-23 2004-06-22 Leo Pharmaceutical Products, Ltd. A/S Pharmaceutical composition
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU5893300A (en) 1999-06-28 2001-01-31 Procter & Gamble Company, The Cosmetic compositions containing vitamin b3
DE29916231U1 (de) 1999-09-15 2000-02-17 Renner Jobst Multivitamin- und -mineralpräparat
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
IL133976A (en) * 2000-01-11 2006-09-05 Dermipsor Ltd Agents for the treatment of skin disorders
US20090098065A1 (en) 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
AU2001242313A1 (en) * 2000-03-21 2001-10-15 Astion Development Aps Chemical complex comprising a pyridine carboxy derivative and an H2 histamine receptor antagonist
ES2298264T3 (es) 2000-10-27 2008-05-16 Leo Pharma A/S Composicion topica que contiene al menos una vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
US6589922B1 (en) * 2001-03-08 2003-07-08 Dow Pharmaceutical Sciences Skin cleanser comprising a steareth, poloxamer, and a glyceryl monoester
US6533190B1 (en) * 2001-08-27 2003-03-18 Yu-Tzu Wang Sprayer having 3 dimensional water screen
EP1461044A4 (en) * 2001-12-03 2007-06-13 Novacea Inc PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
WO2004006887A2 (en) 2002-07-11 2004-01-22 Dermipsor Ltd. Composition and methods for the treatment of skin disorders
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
EP1458678A1 (en) * 2002-11-18 2004-09-22 Teva Pharmaceutical Industries Limited A crystallization method for purification of calcipotriene
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
CN101217868A (zh) 2005-05-10 2008-07-09 德米普瑟尔有限公司 用于皮肤护理的组合物和方法
CN101193641B (zh) * 2005-05-10 2013-05-29 德米普瑟尔有限公司 用于治疗表皮过度增殖疾病的组合物和方法
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US20100162611A1 (en) * 2008-12-31 2010-07-01 Machining Technologies, Inc. Adjustable base for an optic

Also Published As

Publication number Publication date
US20170196897A1 (en) 2017-07-13
IL187238A (en) 2015-06-30
AU2006245283B2 (en) 2012-11-01
EP1879595B1 (en) 2014-09-24
KR20080012339A (ko) 2008-02-11
CA2608023C (en) 2015-08-18
IL187238A0 (en) 2008-06-05
BRPI0609630A2 (pt) 2010-04-20
US20160015723A1 (en) 2016-01-21
CN101193641A (zh) 2008-06-04
WO2006120682A3 (en) 2007-01-25
EP1879595A2 (en) 2008-01-23
ZA200710371B (en) 2009-07-29
US9173835B2 (en) 2015-11-03
CA2608023A1 (en) 2006-11-16
HK1112194A1 (en) 2008-08-29
AU2006245283A1 (en) 2006-11-16
JP2008540514A (ja) 2008-11-20
US9603861B2 (en) 2017-03-28
CN101193641B (zh) 2013-05-29
US20090131488A1 (en) 2009-05-21
EP1879595A4 (en) 2009-07-15
DK1879595T3 (en) 2015-01-05
WO2006120682A2 (en) 2006-11-16
NZ563270A (en) 2010-11-26

Similar Documents

Publication Publication Date Title
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
RS50812B (sr) Suva granulisana kompozicija koja sadrži emtricitabin i tenofovir df
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
ECSP045307A (es) Combinacion de compuestos organicos
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
AR049519A1 (es) Composicion en forma de spray que comprende una asociacion de activos farmaceuticos,como propionato de clobetasol y calcitrol, una fase alcoholica y una fase oleosa
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
EP2144590A4 (en) TREATMENT COMPOSITIONS FOR THE SKIN AND METHODS
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
ATE432710T1 (de) Pharmazeutische zusammensetzungen, die diaminooxidase enthalten
ATE442864T1 (de) Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff
DK1771180T4 (da) Sammensætning i form af en spray, der omfatter en kombination af clobetasolpropionat og calcitriol, en alkoholfase og en oliefase
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ITMI20040954A1 (it) Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
BRPI0520821A2 (pt) formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
WO2008097539A3 (en) Multi-modal absorption, medicine-delivery lozenge, and use thereof
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid